Clinical Trial Update: Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study comparing bosutinib plus exemestane versus exemestane alone in postmenopausal women with advanced breast cancer was terminated, with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)
• BOSULIF (bosutinib)

Snippet

Sponsor: Pfizer | Conditions: Advanced Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-11-05